Edward Tenthoff
Stock Analyst at Piper Sandler
(2.38)
# 2,494
Out of 4,944 analysts
180
Total ratings
40.35%
Success rate
-0.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $304 → $449 | $432.47 | +3.82% | 14 | Aug 1, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $5.21 | +187.91% | 5 | Jul 15, 2025 | |
| INO Inovio Pharmaceuticals | Initiates: Overweight | $5 | $1.69 | +195.86% | 1 | Jul 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $57.27 | +83.34% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.79 | +154.71% | 7 | Jun 16, 2025 | |
| BMEA Biomea Fusion | Assumes: Overweight | $7 | $1.73 | +305.80% | 1 | Jun 3, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $6 → $9 | $6.84 | +31.58% | 4 | May 29, 2025 | |
| ITOS iTeos Therapeutics | Maintains: Overweight | $16 → $12 | $10.13 | +18.46% | 1 | May 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | $24 → $14 | $7.09 | +97.60% | 7 | May 2, 2025 | |
| IPSC Century Therapeutics | Maintains: Overweight | $4 → $2 | $0.54 | +267.65% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $12.25 | +291.84% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.20 | +57.89% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $36.95 | +111.10% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $7.82 | +283.63% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $45 | $20.00 | +125.06% | 11 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $69 | $26.89 | +156.60% | 12 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $9.36 | +594.44% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.44 | +1,150.00% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.28 | +322.71% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $3.15 | +534.92% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.36 | +121.40% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.79 | +280.81% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.43 | +261.17% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.13 | +430.97% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.73 | +189.02% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $40.74 | +37.46% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $10.70 | +2,217.76% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $2.93 | +2,976.92% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $15.92 | +1,030.65% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $17.25 | +155.07% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.34 | +404.09% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.90 | +34,273,584.21% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $645.95 | -45.20% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.48 | +9,021.62% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $395.99 | -18.43% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $38.47 | -6.42% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.30 | +1,823.08% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $1.53 | +9,703.92% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $1.28 | +4,040.63% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $0.62 | +224,290.24% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $561.28 | - | 11 | Feb 13, 2017 |
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $304 → $449
Current: $432.47
Upside: +3.82%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $5.21
Upside: +187.91%
Inovio Pharmaceuticals
Jul 9, 2025
Initiates: Overweight
Price Target: $5
Current: $1.69
Upside: +195.86%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $57.27
Upside: +83.34%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.79
Upside: +154.71%
Biomea Fusion
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.73
Upside: +305.80%
Fulcrum Therapeutics
May 29, 2025
Maintains: Overweight
Price Target: $6 → $9
Current: $6.84
Upside: +31.58%
iTeos Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $10.13
Upside: +18.46%
Arvinas
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $7.09
Upside: +97.60%
Century Therapeutics
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.54
Upside: +267.65%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $12.25
Upside: +291.84%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.20
Upside: +57.89%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $36.95
Upside: +111.10%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $7.82
Upside: +283.63%
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $20.00
Upside: +125.06%
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $26.89
Upside: +156.60%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $9.36
Upside: +594.44%
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $1.44
Upside: +1,150.00%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $8.28
Upside: +322.71%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $3.15
Upside: +534.92%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.36
Upside: +121.40%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.79
Upside: +280.81%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.43
Upside: +261.17%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.13
Upside: +430.97%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.73
Upside: +189.02%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $40.74
Upside: +37.46%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $10.70
Upside: +2,217.76%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $2.93
Upside: +2,976.92%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $15.92
Upside: +1,030.65%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $17.25
Upside: +155.07%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.34
Upside: +404.09%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.90
Upside: +34,273,584.21%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $645.95
Upside: -45.20%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.48
Upside: +9,021.62%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $395.99
Upside: -18.43%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $38.47
Upside: -6.42%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.30
Upside: +1,823.08%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $1.53
Upside: +9,703.92%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $1.28
Upside: +4,040.63%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $0.62
Upside: +224,290.24%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $561.28
Upside: -